Latest

1 story

Hide weekly roundups

Friday, September 25

Ollin Biosciences registers two Phase 3 trials of OLN324 for diabetic macular edema

Weekly roundup, 2 itemsOllin Biosciences, Inc

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.